ProteoNic and ModiQuest announce collaboration
ProteoNic and ModiQuest announced their collaboration on antibody Expression in mammalian cell culture for use in diagnostic and therapeutic product development and manufacturing. ProteoNic will provide its expertise in construct design and protein expression optimization. ModiQuest will apply its proprietary vectors systems and expertise in high throughput production of high level expressing mammalian cell lines in combination with the UNic(tm) expression technology to manufacture its commercial antibodies in mammalian cell lines.
Jos Raats, Managing Director ModiQuest commented: "ModiQuest is most pleased with this current collaboration. Implementation of ProteoNic's expression optimization cassettes will enable us to develop even better expression vectors and will allow faster progress of our therapeutic and diagnostic programs based on biologicals. Moreover, implementation of ProteoNic's UNic(tm) expression enhancement technology in our expression systems will enable us to offer fast production of even higher protein expressing cell lines for our own programs and as third party services to our customers."
"This collaboration is another great opportunity to expand the validation and track record of the application of our UNic(tm) expression technology in mammalian cell culture", ProteoNic CEO Victor Schut commented. "ModiQuest's expertise in antibody expression strongly supports our technology development and experience in optimizing translation efficiency for a relevant group of commercial proteins commonly expressed in mammalian cell lines. Consequently, our collaboration will provide significant added value beneficial to the clients of ModiQuest. We are very pleased to have created a strong and mutually beneficial long term partnership supporting both scientific and commercial goals."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
